Saturday 17 October 2026
Export CERO’s income statement to Excel — free account
CERo Therapeutics Holdings, Inc.
CERO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow grew 49.7%, each against the same quarter a year earlier.
0.01
0.00
0.00%
Follow CERO
CERo Therapeutics Holdings, Inc. (CERO) P/E ratio
As of 16 October 2026, CERo Therapeutics Holdings, Inc. (CERO) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 68.6× (April 2025); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 68.6×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| VRPX Virpax Pharmaceuticals, Inc. compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| VINC Vincerx Pharma, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | n/m |
| EFTR eFFECTOR Therapeutics, Inc. compare | n/m |
| CERO CERo Therapeutics Holdings, Inc. | 0.0× |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)